Lumida
/APGE
⌘K
Apogee Therapeutics Inc

Apogee Therapeutics Inc

APGE
$135.07USD↓-0.01%-0.01 today

MARKET CAP

10.2B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$135 – $135

52W RANGE

$35
$135

AI Summary

Stalk
StalkMedium

APGE remains in a Stage 2 parabolic advance with strong volume, currently extended above rising EMAs and overbought. Under a speculative strategy, defer new exposure until a shallow pullback into the 9/20-EMA support zone shows reclaim and acceptance.

  • ↑AbbVie acquisition at $135.11/share to close Q3 2026 offers a ~premium to market
  • ↑Phase 2 APEX trial showed 65.9% mid-dose patients hitting EASI-75 vs placebo
  • ↓Q2 2026 net loss of $85.9 M and $67.3 M R&D spend strain margins
Full analysis →
Sales, Adj.
No data
Gross Profit, Adj.
No data
EBITDA, Adj.
EBIT
Net Income